

July 14, 2026

MEDIPAL HOLDINGS CORPORATION
Representative: Shuichi Watanabe, Representative Director, President and CEO
Code number: 7459 (Prime Market, Tokyo Stock Exchange)
Contact: Toshiyuki Ikeuchi,
Executive Officer, Head of Corporate Communications Department,
Corporate Planning Division
Tel: +81-3-3517-5171

Notice Regarding Receipt of Dividends from Consolidated Subsidiaries

MEDIPAL HOLDINGS CORPORATION anticipates receiving dividend payments from eight of our consolidated subsidiaries. As this matter meets the requirements for filing an extraordinary report pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 12 of the Cabinet Office Ordinance on Disclosure of Corporate Affairs, etc., we hereby provide notification as follows.

1. Overview of Dividends

On July 14, 2026, our consolidated subsidiaries resolved to pay dividends from surplus.

- (1) Dividend Amount: 42.1 billion Yen
- (2) Scheduled Date of Receipt: July 15, 2026
- (3) Payers of dividends: 8 consolidated subsidiaries

2. Financial Impact on Business Performance

As a result of these dividends, the above dividend income will be recorded as operating income in the non-consolidated financial statements for the fiscal year ending March 2027. As this dividend is received from consolidated subsidiaries, there is no impact on the consolidated results for the fiscal year ending March 2027.

#

The English version of this document is a translation of the Japanese original and is provided for informational purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. In the event of any inconsistencies or conflicts between the English version and the Japanese original, the Japanese original shall prevail.